Leukaemia (chronic myeloid, first line) - dasatanib, nilotinib and standard-dose imatinib - NICE TAG TA251

1.1 Standard-dose imatinib[1] is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive chronic myeloid leukaemia (CML).

1.2 Nilotinib is recommended as an option for the first-line treatment of adults with chronic phase Philadelphia-chromosome-positive CML if the manufacturer makes nilotinib available with the discount agreed as part of the patient access scheme.

1.3 Dasatinib is not recommended for the first-line treatment of chronic phase Philadelphia-chromosome-positive CML.

1.4 People currently receiving dasatinib that is not recommended according to 1.3 should be able to continue treatment until they and their clinician consider it appropriate to stop.

[1] The summary of product characteristics (SPC) for imatinib states that the recommended dosage of imatinib is 400 mg per day for patients in chronic phase CML.

https://www.nice.org.uk/guidance/TA251